Dyne Therapeutics (DYN, Financial) experienced a significant stock price drop of 5.05%. The share price is now at $33.46 with a trading volume of 251,725 shares and a turnover rate of 0.25%. The stock's fluctuation amplitude is recorded at 4.37%.
Recent financial reports indicate that Dyne Therapeutics generated no revenue, with a net loss of $65.10 million, resulting in an earnings per share of -$0.70. The gross profit stood at -$400,000, and the price-to-earnings ratio was -9.35.
Despite these figures, all nine institutions covering the stock have given it a 'buy' rating, with none recommending a 'hold' or 'sell'.
In the broader biotechnology sector, there's a general decline of 0.70%. However, stocks like Genprex Inc., Biovie Inc., and Gri Bio Inc. have shown significant gains, with Genprex Inc. exhibiting a turnover rate of 9244.49% and an amplitude of 369.73%.
Dyne Therapeutics specializes in treatments for genetically-driven diseases, focusing on muscle disorders. The company is progressing with therapies for conditions like myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. Their leading candidates, DYNE-101 and DYNE-251, are in phase 1/2 clinical trials.
